Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a buy rating in a report published on Saturday morning.

Separately, Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $4.57 on Friday. The company’s fifty day moving average price is $4.20 and its 200-day moving average price is $3.85. The firm has a market capitalization of $190.10 million, a price-to-earnings ratio of 1.11 and a beta of 1.22. Oramed Pharmaceuticals has a one year low of $2.05 and a one year high of $5.19.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52). As a group, equities research analysts expect that Oramed Pharmaceuticals will post 1.24 EPS for the current year.

Insider Activity

In other news, CFO Avraham Gabay sold 73,360 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the completion of the transaction, the chief financial officer directly owned 671,785 shares of the company’s stock, valued at approximately $3,029,750.35. This represents a 9.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Joshua Hexter sold 137,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.46, for a total transaction of $611,020.00. Following the sale, the chief operating officer owned 1,023,384 shares of the company’s stock, valued at approximately $4,564,292.64. This represents a 11.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Kathmere Capital Management LLC purchased a new stake in Oramed Pharmaceuticals in the 1st quarter worth approximately $51,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Oramed Pharmaceuticals during the first quarter valued at approximately $63,000. Redwood Family Wealth LLC purchased a new position in shares of Oramed Pharmaceuticals during the fourth quarter valued at approximately $66,000. XTX Topco Ltd raised its holdings in shares of Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 14,297 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in Oramed Pharmaceuticals in the fourth quarter worth $119,000. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.